Abstract:Immunpathogenese und Genetik Auch beim BS spielt die Neutrophilen- (Hyper-)Aktivierung und die daraus hervorgehende NETosis eine wichtige Rolle. Klinische Befunde Neben den 4 Kardinalsymptomen – nämlich rezidivierende orale Aphthen, genitale Aphthen sowie Haut- und Augenläsionen – bietet das Krankheitsbild zahlreiche weitere Manifestationen, die häufig eine interdisziplinäre Zusammenarbeit erfordern. Dies gilt neben der Augenbeteiligung, die bei inadäquater Behandlung immer noch zur Erblindung führen kann, insbesondere auch für intestinale und zerebrale Manifestationen sowie für die Großgefäß-Vaskulitis. Therapie Eine letzte Überarbeitung der EULAR-Empfehlungen erfolgte 2018. Die Empfehlungen sind mittlerweile als wichtiger Behandlungsleitfaden international etabliert. Die Therapie richtet sich nach der führenden Organbeteiligung. Nachdem 2016 Adalimumab eine Zulassung für die Behandlung der hinteren Augenbeteiligung erhielt, steht mit Apremilast seit 2020 ein weiterer Wirkstoff zur Verfügung. Empfohlen wird das Medikament für die Behandlung rezidivierender oraler Aphthen bei erwachsenen Behçet-Patienten, die einer systemischen Therapie bedürfen. Es besteht dennoch ein weiterer Bedarf an neuen Substanzen. Behçet's syndrome (BS, synonym: Behçet's disease, or Adamantiades-Behçet's disease, ABD) is classified as a vasculitis of variable vessel size and can manifest itself in both arterial and venous vessels. Its extensive and at the same time interindividually very different clinical picture is not uncommon a challenge, both with regard to the diagnosis of this rheumatic systemic disease, which is rather rare in our latitudes, and its therapeutic options. In addition to the four cardinal symptoms of recurrent oral aphthae, genital aphthae, skin and eye lesions, the clinical picture offers numerous other manifestations which often require interdisciplinary cooperation. In addition to the above mentioned ocular involvement, which can still lead to blindness if inadequately treated, this is especially true for intestinal and cerebral manifestations as well as for large vessel vasculitis. A final revision of the European League Against Rheumatism recommendations for the management of Behcet's syndrome (EULAR) was made in 2018, and the recommendations are now established internationally as an important treatment guide. Therapy is based on the leading organ involvement. After adalimumab received approval for the treatment of posterior ocular involvement in 2016, another agent, apremilast, became available in 2020. The drug is recommended for the treatment of recurrent oral aphthae in adult Behçet's patients requiring systemic therapy. Nevertheless, there is a further need for new drugs. This article aims to highlight recent findings in the areas of epidemiology, immunopathogenesis & genetics, clinical findings, and therapy, with an emphasis on clinical relevance. Received: 31 January 2023 Accepted after revision: 08 May 2023 Article published online: 08 February 2024 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Neues zum Behçet-Syndrom

[Update on Behçet syndrome]

Ischaemic Heart Disease in Behçet's Syndrome: a Systematic Review and Meta-Analysis

Behçet's syndrome: one year in review 2024

The clinical manifestations and treatment outcomes of Behçet's disease: A single-center experience

Behçet's Syndrome in a Child: A Case Report and a Review of Literature

A Scientometric Study on Research Trends and Characteristics of Behçet's Disease

Vascular Behçet syndrome: from pathogenesis to treatment

Immunopathogenesis of Behcet's Disease.

Behçet's syndrome: a review for the genitourinary medicine physician

Epidemiology and treatment of Adamantiades–Behçet's disease in Germany: A healthcare claims database study

Prevalence, Clinical Impact, and Management

Neuro-Behçet's syndrome with a severe ocular lesion.

Neuro-Behçet's Syndrome Without Genital Ulcers: A Case Report and Literature Review

Endocarditis, Intra-cardiac Thrombus, and Pulmonary Artery Aneurysm in a Patient with Behcet's Syndrome

De novo manifestations during adalimumab treatment in Behçet’s syndrome

Clinical features of chinese patients with Behçet's disease

Cytokines and Behcet's disease.

Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial

[Panuveitis with oral and genital ulcer misdiagnosed as Behcet's disease: two cases report and literature review].

Folliculitis might be associated with pathergy-positivity in patients with Behçet syndrome